Potential role of fecal microbiota in patients with constipation
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
Experiment 1
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Transplant outcome measurement Transplant outcome measurement,transplant outcome measurement
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Before treatment, After 1st treatment, After 2nd treatment, After 3rd treatment, 2 month follow-up and 3 month follow up
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Donor
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- The donors were healthy individuals without diseases or pathologic conditions potentially associated with changes in the gut microbiota.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 34
- Group 1 sample size Number of subjects in the case (exposed) group
- 4
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 1 month
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- Not specified
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 2
Signature 1
Source: Figure 5
Description: Linear discriminant analysis effect size (LEfSe) analysis of microbial abundance between Donor versus Before treatment, After 1st treatment, After 2nd treatment, After 3rd treatment, 2 month follow-up and 3 month follow up.
Abundance in Group 1: increased abundance in Donor
NCBI | Quality Control | Links |
---|---|---|
Xanthobacteraceae | ||
Asticcacaulis | ||
Faecalibacterium | ||
Dorea | ||
Blautia | ||
Anaerostipes | ||
Lachnospiraceae | ||
Oscillospiraceae |
Revision editor(s): MyleeeA
Experiment 2
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Donor, After 1st treatment, After 2nd treatment, After 3rd treatment, 2 month follow-up and 3 month follow up
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Before treatment
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with chronic functional constipation before Fecal microbiota transplantation treatment.
- Group 0 sample size Number of subjects in the control (unexposed) group
- Not specified
- Group 1 sample size Number of subjects in the case (exposed) group
- Not specified
Lab analysis
Statistical Analysis
Signature 1
Source: Figure 5
Description: Linear discriminant analysis effect size (LEfSe) analysis of microbial abundance between Before treatment versus Donor, After 1st treatment, After 2nd treatment, After 3rd treatment, 2 month follow-up and 3 month follow up.
Abundance in Group 1: increased abundance in Before treatment
NCBI | Quality Control | Links |
---|---|---|
Phascolarctobacterium | ||
Bacteroides |
Revision editor(s): MyleeeA
Experiment 3
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Donor, Before treatment, After 2nd treatment, After 3rd treatment, 2 month follow-up and 3 month follow up
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- After 1st treatment
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with chronic functional constipation after first treatment with Fecal microbiota transplantation.
Lab analysis
Statistical Analysis
Signature 1
Source: Figure 5
Description: Linear discriminant analysis effect size (LEfSe) analysis of microbial abundance between After 1st treatment versus Donor, Before treatment, After 2nd treatment, After 3rd treatment, 2 month follow-up and 3 month follow up.
Abundance in Group 1: increased abundance in After 1st treatment
NCBI | Quality Control | Links |
---|---|---|
Odoribacter |
Revision editor(s): MyleeeA
Experiment 4
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Donor, Before treatment, After 1st treatment, After 3rd treatment, 2 month follow-up and 3 month follow up
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- After 2nd treatment
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with chronic functional constipation after second treatment with Fecal microbiota transplantation.
Lab analysis
Statistical Analysis
Signature 1
Source: Figure 5
Description: Linear discriminant analysis effect size (LEfSe) analysis of microbial abundance between After 2nd treatment versus Donor, Before treatment, After 1st treatment, After 3rd treatment, 2 month follow-up and 3 month follow up.
Abundance in Group 1: increased abundance in After 2nd treatment
NCBI | Quality Control | Links |
---|---|---|
Bilophila |
Revision editor(s): MyleeeA
Experiment 5
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Donor, Before treatment, After 1st treatment, After 2nd treatment, 2-month follow up and 3-month follow up
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- After 3rd treatment
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with chronic functional constipation after third treatment with Fecal microbiota transplantation.
Lab analysis
Statistical Analysis
Signature 1
Source: Figure 5
Description: Linear discriminant analysis effect size (LEfSe) analysis of microbial abundance between After 3rd treatment versus Donor, Before treatment, After 1st treatment, After 2nd treatment, 2-month follow up and 3-month follow up.
Abundance in Group 1: increased abundance in After 3rd treatment
NCBI | Quality Control | Links |
---|---|---|
Dialister | ||
Megamonas |
Revision editor(s): Anne-mariesharp
Experiment 6
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Donor, Before treatment, After 1st treatment, After 2nd treatment, After 3rd treatment and 3-month follow up
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- 2-month follow up
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with chronic functional constipation after treatment with Fecal microbiota transplantation and at 2-months of follow up
Lab analysis
Statistical Analysis
Signature 1
Source: Figure 5
Description: Linear discriminant analysis effect size (LEfSe) analysis of microbial abundance between 2-month follow up versus Donor, Before treatment, After 1st treatment, After 2nd treatment, After 3rd treatment and 3-month follow up.
Abundance in Group 1: increased abundance in 2-month follow up
NCBI | Quality Control | Links |
---|---|---|
Acidaminococcus | ||
Butyricimonas |
Revision editor(s): Anne-mariesharp
Experiment 7
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Donor, Before treatment, After 1st treatment, After 2nd treatment, After 3rd treatment and 2-month follow up
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- 3-month follow up
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with chronic functional constipation after treatment with Fecal microbiota transplantation and at 3-months of follow up
Lab analysis
Statistical Analysis
Signature 1
Source: Figure 5
Description: Linear discriminant analysis effect size (LEfSe) analysis of microbial abundance between 3-month follow up versus Donor, Before treatment, After 1st treatment, After 2nd treatment, After 3rd treatment and 2-month follow up.
Abundance in Group 1: increased abundance in 3-month follow up
NCBI | Quality Control | Links |
---|---|---|
Acinetobacter | ||
Desulfobulbaceae | ||
Geodermatophilus | ||
Kingella | ||
Luteimonas | ||
Pleomorphomonas | ||
Synechococcus | ||
Thalassospira | ||
Xenococcaceae | ||
ASSO_13ASSO_13 | ||
mle1_48mle1_48 |
Revision editor(s): Anne-mariesharp